Burns LJ, Miller JP, Confer DL

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 195-204
Archivo PDF: 685.64 Kb.

RESUMEN

El trasplante alogénico de células hematopoyéticas (TACH) es una terapia útil para muchos pacientes con enfermedades hematológicas malignas y no malignas. Aunque un hermano con antígeno leucocitario humano (HLA) compatible es el donador de elección para un TACH, la mayoría de los pacientes con necesidad de trasplantarse no tienen un hermano compatible, por tanto, debe identificarse a un donador alternativo. El Programa Nacional de Donadores de Médula Ósea de Estados Unidos (NMDP)/Be The Match opera el registro mundial más grande de adultos donadores y unidades de sangre de cordón umbilical. En este trabajo revisamos la actividad en los primeros años del NMDP y los esfuerzos realizados en este campo para llevar a cabo avances a través de la investigación, así como las colaboraciones globales para facilitar el trasplante a todos los pacientes que lo requieren.

REFERENCIAS (EN ESTE ARTÍCULO)

1. McCullough J, Perkins HA, Hansen J. The National Marrow Donor Program with emphasis on the early years. Transfusion 2006;46:1248-1256.

2. McElligott MD, Menitove JE, Aster RH. Recruitment of unrelated persons as bone marrow donors. Transfusion 1986;26:309-314.

3. Stoncek DF, Strand RD, Hofkes CL, McCullough J. Comparison of the effectiveness of potential marrow donors recruited from apheresis donors or whole blood donors through appeals to the general public. Transfusion 1991;31:138-141.

4. McCullough J, Scott EP, Halagan N, Strand R, McGlave P. Effectiveness of a regional bone marrow donor program. JAMA 1988;259:3286-3289.

5. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. N Engl J Med 2014;317:339-348.

6. Dehn J, Buck K, Maiers M et al. 8/8 and 10/10 high-resolution match rate for the Be The Match unrelated donor registry. Biol Blood Marrow Transplant 2015;21:137-141.

7. Ballen KK, King RJ, Chitphbakdithai P et al. The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2008;14:2-7.

8. Spellman S, Setterholm M, Maiers M et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow. Biol Blood Marrow Transplant 2008;14:37-44.

9. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576-4583.

10. Hurley CK, Woolfrey A, Wang T et al. The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. Blood 2013;121:4800-4806.

11. Fernández-Viña M, Klein JP, Haagenson M et al. Multiple mismatches at the low expression HLA loci DP, DQ and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood 2013;121:4603-4610.

12. Fernández-Viña M, Wang T, Lee SJ et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood 2014;123:1270-1278.

13. Pidala J, Lee SJ, Woo Ahn K et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood 2014;124:2596-2606.

14. Howard CA, Fernández-Viña MA, Appelbaum FR et al. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2015;21:4-7.

15. Horowitz MM. The Blood and Marrow Transplant Clinical Trials Network: an effective infrastructure for addressing important issues in hematopoietic cell transplantation: steering committee of the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2016; Jul 11. pii: S1083-8791(16)30219-1. doi: 10.1016/j. bbmt.2016.07.003. [Epub ahead of print] Review.

16. Monos D and Maiers MJ. Progressing towards the complete and thorough characterization of the HLA genes by NGS (or single-molecule DNS sequencing): consequences, opportunities and challenges. Hum Immunol 2015;76:883-886.

17. Cooley S, Weisdorf DJ, Guethlein LA et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411-2419.

18. Bachanova V, Weisdorf DJ, Wang T et al. Donor KIR B genotype improves progression-free survival of non- Hodgkin lymphoma patients receiving unrelated donor transplantation. Biol Blood Marrow Transplant 2016; May 21. pii: S1083-8791(16)30088-X. doi: 10.1016/j. bbmt.2016.05.016. [Epub ahead of print]